What does this research mean for the field?

Only 5 out of 77 evaluated targeted NGS panels captured all recommended biomarkers for metastatic non-small cell lung cancer (mNSCLC). Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine if targeted next-generation sequencing (NGS) panels include all guideline-recommended biomarkers for metastatic non-small cell lung cancer (mNSCLC).

March 2, 2026The American Journal of Managed Care1 citations

Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers?

View Full Paper

JRJade ReynoldsCurry College SPSiyang PengIllumina (United States)EBElizabeth BrouwerBehavioral Tech Research, Inc.

Key Points

To determine if targeted next-generation sequencing (NGS) panels include all guideline-recommended biomarkers for metastatic non-small cell lung cancer (mNSCLC).
Evaluated 77 unique targeted NGS panels
Assessed compliance with guidelines for biomarkers
Identified specific panels that captured all relevant biomarkers.
Only 5 out of 77 panels included all recommended biomarkers for mNSCLC
High variability in biomarker coverage across panels
Indicates significant gaps in meeting treatment standards.

Abstract

Of 77 unique panels evaluated, only 5 captured all recommended biomarkers for mNSCLC. Ensuring targeted panels assess all relevant biomarkers is crucial for optimal patient treatment.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers?

Key Points

Abstract

Cite This Study